title: Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
abstract: The in vitro activity of ceftibuten was studied in 572 bacterial strains and was compared with the activity of other orally administered beta-lactams. Ceftibuten displayed high activity against the Enterobacteriaceae, generally being 16-fold more active than cefuroxime, cefaclor, cephalexin, or amoxicillin-clavulanic acid. Its activity was comparable to cefixime. There was little ceftibuten or cefixime activity against staphylococci (MIC90s greater than or equal to 64 micrograms/ml) and reduced activity against Streptococcus pneumoniae (MIC90, 16 micrograms/ml). Haemophilus influenzae and Neisseria spp. were highly susceptible to ceftibuten and cefixime. The protein binding of ceftibuten was 77%, and the primary target site was PBP 3. A high degree of stability to beta-lactamase hydrolysis was observed.
authors.affiliation: Department of Medical Microbiology, Dudley Road Hospital, Birmingham, United Kingdom.
authors.forename: R
authors.initials: R
authors.lastname: Wise
authors.forename: J M
authors.initials: JM
authors.lastname: Andrews
authors.forename: J P
authors.initials: JP
authors.lastname: Ashby
authors.forename: D
authors.initials: D
authors.lastname: Thornber
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D000077722:Ceftibuten; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D009343:Neisseria / Q000187:drug effects; D006113:United Kingdom; D001618:beta-Lactamases / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D001618:beta-Lactamases; D000077722:Ceftibuten